Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Head And Neck Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Head And Neck Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Head And Neck Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Breast Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Breast Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Lung Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Lung Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Sarcomas: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Sarcomas

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Endometrial Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Endometrial Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Kidney Cancer (Renal Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Kidney Cancer (Renal Cell Cancer)

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Fallopian Tube Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Pancreatic Ductal Adenocarcinoma

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Colorectal Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Colorectal Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Ovarian Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Prostate Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Prostate Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Metastatic Prostate Cancer

Data Insights

HB-0045 by Huabo Biopharm (Shanghai) for Peritoneal Cancer: Likelihood of Approval

HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - HB-0045 in Peritoneal Cancer